IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by WASHINGTON TRUST Co

WASHINGTON TRUST Co lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.4% during the fourth quarter, HoldingsChannel reports. The fund owned 101,414 shares of the medical research company’s stock after selling 2,540 shares during the period. WASHINGTON TRUST Co’s holdings in IQVIA were worth $19,929,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. FMR LLC increased its holdings in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after purchasing an additional 804,963 shares in the last quarter. JPMorgan Chase & Co. grew its position in IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after buying an additional 583,396 shares during the period. Impax Asset Management Group plc increased its holdings in IQVIA by 9.7% in the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after buying an additional 157,809 shares in the last quarter. Nordea Investment Management AB lifted its position in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of IQVIA by 3.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,226,083 shares of the medical research company’s stock worth $290,545,000 after acquiring an additional 39,772 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on IQV shares. Robert W. Baird decreased their target price on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 21st. Deutsche Bank Aktiengesellschaft cut their price objective on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research report on Friday, November 1st. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Morgan Stanley lifted their price target on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a report on Tuesday. Finally, Stifel Nicolaus reduced their price target on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Five research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $251.67.

IQVIA Stock Performance

Shares of IQV stock opened at $193.65 on Friday. The company’s fifty day simple moving average is $200.59 and its 200-day simple moving average is $218.51. The company has a current ratio of 0.84, a quick ratio of 0.81 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The company has a market cap of $35.15 billion, a PE ratio of 25.82, a P/E/G ratio of 2.25 and a beta of 1.48.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.81 EPS for the current year.

Insider Transactions at IQVIA

In other IQVIA news, Director John G. Danhakl bought 1,275 shares of IQVIA stock in a transaction dated Tuesday, December 3rd. The stock was bought at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the purchase, the director now owns 1,275 shares in the company, valued at $255,739.50. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.60% of the company’s stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.